Management of Psychotic Features with Hallucinations

First-Line Treatment: Atypical Antipsychotics

The British Journal of Psychiatry recommends atypical antipsychotics as first-line treatment for patients with psychotic features and hallucinations, with risperidone 2 mg/day or olanzapine 7.5-10 mg/day as appropriate initial target doses 1, 2
Atypical antipsychotics produce significantly fewer extrapyramidal symptoms and lower risk of tardive dyskinesia while providing comparable control of psychosis 1, 2
Atypical antipsychotics are better tolerated even at low doses, which encourages future medication adherence 1, 2

The initial target dose for risperidone is 2 mg/day, with a maximum dose in first-episode psychosis of 4 mg/day 1, 2, 3
Doses of risperidone above 4-6 mg/day do not demonstrate greater efficacy and are associated with more extrapyramidal symptoms 3
The initial target dose for olanzapine is 7.5-10 mg/day, and it is generally well tolerated with a lower risk of extrapyramidal effects 1, 2, 4, 5
Quetiapine has an initial dose of 12.5 mg twice daily, with a maximum dose of 200 mg twice daily, and is more sedating, requiring monitoring for transient orthostatic hypotension 4, 5

Typical antipsychotics should be reserved as second-line therapy only for patients who cannot tolerate or do not respond to atypical agents, due to the significant risk of severe side effects involving cholinergic, cardiovascular, and extrapyramidal systems 4, 5
Irreversible tardive dyskinesia develops in 50% of elderly patients after continuous use of typical antipsychotics for 2 years 4, 5

An antipsychotic (typical or atypical) can be used as effective monotherapy for both agitation management and initial drug therapy in acutely agitated patients with psychosis 6
For cooperative patients, a combination of oral lorazepam and oral risperidone can be used, while for rapid sedation, droperidol may be considered over haloperidol 6

The dose titration strategy should start with low initial doses to minimize side effects, increasing only at widely spaced intervals (14-21 days) after initial titration, and titrating within limits of sedation and emergence of extrapyramidal side effects 1, 2
It is essential to avoid exceeding maximum recommended doses, as this only increases side effects without improving efficacy, and to avoid extrapyramidal side effects to encourage future adherence 1, 2, 3
Before initiating treatment, it is crucial to rule out physical illnesses that can cause psychosis and review reasons for treatment failure if positive symptoms persist after trials of two first-line atypical antipsychotics 1, 2

The American College of Emergency Physicians recommends intramuscular olanzapine 10 mg as first-line therapy for acute psychotic agitation, or alternatively haloperidol 5 mg IM combined with lorazepam 2 mg IM, with olanzapine preferred due to superior tolerability and equivalent efficacy 7

Combination of haloperidol 5 mg plus lorazepam 2-4 mg IM produces significantly greater reduction in agitation compared to either agent alone at 1 hour, according to the American College of Emergency Physicians 7
Haloperidol monotherapy carries a 20% risk of extrapyramidal side effects, which can be mitigated by combination with benzodiazepines, as recommended by the American College of Emergency Physicians 7
Haloperidol 10 mg plus promethazine 25-50 mg achieved equal tranquilization rates (96%) compared to lorazepam 4 mg at 4 hours, as reported by the American College of Emergency Physicians 7

Using haloperidol monotherapy without benzodiazepine co-administration increases the risk of acute dystonia and akathisia, according to the American College of Emergency Physicians 7
Lorazepam 2 mg produces a more rapid decrease in agitation scores at 1-3 hours compared to haloperidol 5 mg, but combination therapy is superior to either alone, as recommended by the American College of Emergency Physicians 7